1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Alzheimer’s Therapeutic Market
2.2. Global Alzheimer’s Therapeutic Market, By Drug Type, 2023 (US$ Million)
2.3. Global Alzheimer’s Therapeutic Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Alzheimer’s Therapeutic Market: Competitive Analysis
3.1. Market Positioning of Key Alzheimer’s Therapeutic Market Vendors
3.2. Strategies Adopted by Alzheimer’s Therapeutic Market Vendors
3.3. Key Industry Strategies
4. Alzheimer’s Therapeutic Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Alzheimer’s Therapeutic Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Memantine Hydrochloride
5.3.2. Donepezil Hydrochloride
5.3.3. Rivastigmine
5.3.4. Galantamine Hydrobromide
5.3.5. Pipeline Analysis
5.3.5.1. Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
5.3.5.1.1. ENA713
5.3.5.1.2. Flutemetamol (18F)
5.3.5.1.3. LY450139
5.3.5.1.4. Dimebon
5.3.5.1.5. Aripiprazole/ BMS-337039
5.3.5.2. Tabular Representation of Phase II and I Drugs


6. North America Alzheimer’s Therapeutic Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
6.3.Alzheimer’s Therapeutic Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)

7. UK and European Union Alzheimer’s Therapeutic Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.Alzheimer’s Therapeutic Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)

8. Asia Pacific Alzheimer’s Therapeutic Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.Alzheimer’s Therapeutic Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)

9. Latin America Alzheimer’s Therapeutic Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
9.3.Alzheimer’s Therapeutic Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)

10. Middle East and Africa Alzheimer’s Therapeutic Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
10.3.Alzheimer’s Therapeutic Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Alzheimer’s Therapeutic Market: By Drug Type, 2022-2032, USD (Million)

11. Company Profile
11.1. Pfizer Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Novartis International AG
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Axovant Sciences Ltd.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Acadia Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Biotie Therapies
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Astra Zeneca plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Eli Lilly, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. F. Hoffman Le Roche
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Merck & Co.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. H. Lundbeck A/S
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Takeda Pharmaceutical Company Ltd.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives